Efficacy and safety of Iptacopan in patients with IgA nephropathy (IgAN): Interim analysis (IA) of the Phase 3 APPLAUSE-IgAN study - Lead Autho/Presenter: Thomas Hach
Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgA Nephropathy )IgAN): Interim Analysis of the Phase 3 APPLAUSE-IgAN Study - Lead Author/Presenter: Thomas Hach
Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy (IgAN) with Baseline eGFR 20-<30mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results - Lead Author/Presenter: Thomas Hach
Update to the long-term safety and efficacy of Iptacopan in C3G: 33-month extension study data from patients enrolled in a Phase 2 study - Lead Author/Presenter: Barratt J
